Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Jan;4(1):90-7.
doi: 10.1111/j.1538-7836.2005.01697.x.

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation

J Kienast  1 , M Juers, C J Wiedermann, J N Hoffmann, H Ostermann, R Strauss, H-O Keinecke, B L Warren, S M Opal; KyberSept investigators
Affiliations
Free article
Clinical Trial

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation

J Kienast et al. J Thromb Haemost. 2006 Jan.
Free article

Abstract

Background: Disseminated intravascular coagulation (DIC) is a serious complication of sepsis that is associated with a high mortality.

Objectives: Using the adapted International Society on Thrombosis and Haemostasis (ISTH) diagnostic scoring algorithm for DIC, we evaluated the treatment effects of high-dose antithrombin (AT) in patients with severe sepsis with or without DIC.

Patients and methods: From the phase III clinical trial in severe sepsis (KyberSept), 563 patients were identified (placebo, 277; AT, 286) who did not receive concomitant heparin and had sufficient data for DIC determination.

Results: At baseline, 40.7% of patients (229 of 563) had DIC. DIC in the placebo-treated patients was associated with an excess risk of mortality (28-day mortality: 40.0% vs. 22.2%, P < 0.01). AT-treated patients with DIC had an absolute reduction in 28-day mortality of 14.6% compared with placebo (P = 0.02) whereas in patients without DIC no effect on 28-day mortality was seen (0.1% reduction in mortality; P = 1.0). Bleeding complications in AT-treated patients with and without DIC were higher compared with placebo (major bleeding rates: 7.0% vs. 5.2% for patients with DIC, P = 0.6; 9.8% vs. 3.1% for patients without DIC, P = 0.02).

Conclusions: High-dose AT without concomitant heparin in septic patients with DIC may result in a significant mortality reduction. The adapted ISTH DIC score may identify patients with severe sepsis who potentially benefit from high-dose AT treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Studies on therapeutic effects and pathological features of an antithrombin preparation in septic disseminated intravascular coagulation patients.
    Sakamoto Y, Inoue S, Iwamura T, Yamashita T, Nakashima A, Nishimura Y, Koami H, Imahase H, Goto A, Yamada KC, Mashiko K, Yokota H. Sakamoto Y, et al. Yonsei Med J. 2013 May 1;54(3):686-9. doi: 10.3349/ymj.2013.54.3.686. Yonsei Med J. 2013. PMID: 23549815 Free PMC article.
  • Temporal Trends, Predictors, and Outcomes of Disseminated Intravascular Coagulation in Hospitalizations With Sepsis.
    Solanki D, Lal D, Sunny A, Han X, Iyanar S, Halder A, Mullangi S, Desai M, Khan U, Theli A, Devani H, Kumar P, Patel AA, Lekkala M. Solanki D, et al. Cureus. 2022 Jul 30;14(7):e27477. doi: 10.7759/cureus.27477. eCollection 2022 Jul. Cureus. 2022. PMID: 36060388 Free PMC article.
  • Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy.
    Iba T, Umemura Y, Watanabe E, Wada T, Hayashida K, Kushimoto S; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation. Iba T, et al. Acute Med Surg. 2019 Apr 1;6(3):223-232. doi: 10.1002/ams2.411. eCollection 2019 Jul. Acute Med Surg. 2019. PMID: 31304023 Free PMC article. Review.
  • Limb ischemia in patients with COVID-19.
    de Oliveira JCP, Araujo WJB, Belczak SQ, Erzinger FL, de Oliveira LMP, Marques MA, Sarquis LM, Gutfilen B. de Oliveira JCP, et al. J Vasc Bras. 2021 Jun 9;20:e20210004. doi: 10.1590/1677-5449.210004. J Vasc Bras. 2021. PMID: 34211543 Free PMC article. Review.
  • The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020).
    Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, Kakihana Y, Kawasaki T, Kushimoto S, Kuroda Y, Kotani J, Shime N, Taniguchi T, Tsuruta R, Doi K, Doi M, Nakada TA, Nakane M, Fujishima S, Hosokawa N, Masuda Y, Matsushima A, Matsuda N, Yamakawa K, Hara Y, Sakuraya M, Ohshimo S, Aoki Y, Inada M, Umemura Y, Kawai Y, Kondo Y, Saito H, Taito S, Takeda C, Terayama T, Tohira H, Hashimoto H, Hayashida K, Hifumi T, Hirose T, Fukuda T, Fujii T, Miura S, Yasuda H, Abe T, Andoh K, Iida Y, Ishihara T, Ide K, Ito K, Ito Y, Inata Y, Utsunomiya A, Unoki T, Endo K, Ouchi A, Ozaki M, Ono S, Katsura M, Kawaguchi A, Kawamura Y, Kudo D, Kubo K, Kurahashi K, Sakuramoto H, Shimoyama A, Suzuki T, Sekine S, Sekino M, Takahashi N, Takahashi S, Takahashi H, Tagami T, Tajima G, Tatsumi H, Tani M, Tsuchiya A, Tsutsumi Y, Naito T, Nagae M, Nagasawa I, Nakamura K, Nishimura T, Nunomiya S, Norisue Y, Hashimoto S, Hasegawa D, Hatakeyama J, Hara N, Higashibeppu N, Furushima N, Furusono H, Matsuishi Y, Matsuyama T, Minematsu Y, Miyashita R, Miyatake Y, Moriyasu M, Yamada T, Yamada H, Yamamoto R, Yoshida T, Yoshida Y, Yoshimura J, Yotsumoto R, Yonekura H, Wada T, Watanabe E, Aoki M, Asai H, Abe T, Igarashi Y, Iguch… See abstract for full author list ➔ Egi M, et al. J Intensive Care. 2021 Aug 25;9(1):53. doi: 10.1186/s40560-021-00555-7. J Intensive Care. 2021. PMID: 34433491 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

Substances